Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 24, 2012; 78 (1 Supplement) April 24,2012

A Novel Marker for Neuroinflammation in Diabetic Neuropathy (P03.195)

Leila Maybodi, Norman Ende, Hongxin Chen, Nizar Souayah
First published February 8, 2016,
Leila Maybodi
1 New Jersey Medical School New York NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norman Ende
2 New Jersey Medical School Newark NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongxin Chen
3 New Jersey Medical School Newark NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nizar Souayah
4 New Jersey Medical School Westfield NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
A Novel Marker for Neuroinflammation in Diabetic Neuropathy (P03.195)
Leila Maybodi, Norman Ende, Hongxin Chen, Nizar Souayah
Neurology Apr 2012, 78 (1 Supplement) P03.195;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To report a new marker for neuroinflammation in diabetic distal symmetric sensorimotor polyneuropathy.

Background A conduction slowing seldom fulfilling the AAN criteria for CIDP has been observed in diabetic distal symmetric sensorimotor polyneuropathy (DSP) in several studies.

Design/Methods: Urine secretory phopholipase activity (sPLA2) was measured in 34 DSP patients with at least one nerve conduction velocity (CV) slowing in the AAN demyelinating range (DSPs), 52 diabetic patients without CV slowing (DSPns), 5 diabetic patients without neuropathy (DWN) and 5 CIDP. Using multiple linear regression analysis, we related conduction velocity, (CV) ,distal latency (DL) and F latency to distal CMAP amplitude of median, ulnar, peroneal and tibial nerve in 76 patients with CIDP. The developed equations that assessed the range of slowing in CIDP were used to study conduction slowing in the above DSP patients.

Results: sPLA2 activity was significantly higher is the DSPs in nmol/min/ml (1411.2±281.09) and CIDP (1349.1 ±328.45) compared to controls (581.56±73.95) p<0.001. sPLA2 activity was significantly higher in DSPs group compared to DSPns group (892.91 128.28)p<0.001. However there was no significant difference in sPA2 activity between DSPns, DWN (835.66± 316.77) and control groups. In control group 95% of patients have an sPLA2 activity less than 1350 nmol/min/ml. 21 (54%) patients from DSPs and only 10(16%) patients from DSPns have at least two nerves with CV in the range predicted by the developed equations. Among the above patients 10 (30%) in the DSPs and only 1 (2%) DSPns patients have a sPLA2 activity more than 1350 nmol/min/ml.

Conclusions: Urine sPLA2 activity is significantly higher in DSPn compared to DSPns. When combined to CV slowing, it could be used as a marker of inflammatory demyelination in diabetic neuropathy.

Disclosure: Dr. Maybodi has nothing to disclose. Dr. Ende has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Souayah has received personal compensation for activities with Walgreens as a consultant. Dr. Souayah has received research support from Talecris.

Tuesday, April 24 2012, 14:00 pm-18:30 pm

  • Copyright © 2011 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise